Development of neurotrophic factor therapy for Alzheimer's disease

CIBA Foundation Symposia

Volumn , Issue 196, 1996, Pages 54-69

  Hefti, Franz ^a,b   Armanini, Mark P ^a   Beck, Klaus D ^a   Caras, Ingrid W ^a   Chen, Karen S ^a   Godowski, Paul J ^a   Goodman, Laurie J ^a   Hammonds, R Glenn ^a   Mark, Melanie R ^a   Moran, Paul ^a   Nishimura, Merry C ^a   Phillips, Heidi S ^a   Shih, Ai ^a   Valverde, Janet ^a   Winslow, John W ^a  

^a GENENTECH INC   (United States)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NERVE GROWTH FACTOR; NERVE PROTEIN; SOMATOMEDIN C;

ALZHEIMER DISEASE; ANIMAL; BRAIN CORTEX; CYTOLOGY; GENETICS; HIPPOCAMPUS; HUMAN; MYELIN SHEATH; NERVE CELL; PHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CEREBRAL CORTEX; HIPPOCAMPUS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MYELIN SHEATH; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEURONS;

EID: 0030337502     PISSN: 03005208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Beck KD, Hefti F 1993 Neurotrophic factor therapy of Alzheimer's disease. Clin Neurosci 1:219-224
2. Beck KD, Powell-Braxton L, Widmer HR, Valverde J, Hefti F 1995 Mice homozygous for disrupted insulin-like growth factor I gene display reduced myelination in the CNS and reduced numbers of hippocampal granule and parvalbumin-containing neurons. Neuron 4:717-730
3. Chen KS, Nishimura MC, Broz S, Crowley C, Phillips HS 1993 Assessment of learning and memory performance in mice heterozygous for the nerve growth factor deletion. Soc Neurosci Abstr 19:1683
4. Chen KS, Nishimura MC, Spencer S, Crowley C, Phillips HS 1994 Learning, memory, and the basal forebrain cholinergic system in aged mice heterozygous for the nerve growth factor deletion. Soc Neurosci Abstr 20:856
5. Crowley C, Spencer SD, Nishimura MC et al 1994 Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 76:1001-1011
6. Davis KL, Thai LJ, Gamzu ER et al 1992 A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's diseases. New Engl J Med 327:1253-1259
7. Davis S, Gale NW, Aldrich TH et al 1994 Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 266: 816-819
8. DeKosky ST, Harbaugh RE, Schmitt FA et al 1992 Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Ann Neurol 32:625-632
9. Eagger SA, Levy R, Sahakian BJ 1991 Tacrine in Alzheimer's disease. Lancet 337: 989-994
10. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowski CH, Dolan-Ureno J 1992 A controlled trial of tacrine in Alzheimer's disease. JAMA 268:2523-2529
11. Fischer W, Bjorklund A, Chen K, Gage FH 1991 NGF improves spatial memory in aged rodents as a function of age. J Neurosci 11:1889-1906
12. Fischer W, Wictorin K, Björklund A, Williams LR, Varon S, Gage FH 1987 Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329:65-68
13. Goedert M, Fine A, Dawbarn D, Wilcock GK, Chao MV 1989 Nerve growth factor receptor mRNA distribution in human brain: normal levels in basal forebrain in Alzheimer's disease. Mol Brain Res 5:1-7
14. Graham DK, Dawson TL, Mullaney HR, Snodgrass HS, Earp HS 1994 Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth & Differ 5:647-657
15. Hefti F 1994 Neurotrophic factor therapy for nervous system degenerative diseases. J Neurobiol 25:1418-1435
16. Hefti F, Beck KD, Ohsawa F 1993 Pharmacology of neurotrophic factors. Neurodegen Disord Current Drugs 139-158
17. Hefti F, Schneider L 1989 Rationale for the planned clinical trials with nerve growth factor in Alzheimer's disease. Psychiatr Dev 4:297-315
18. Lehericy S, Hirsch EC, Cervera-Pierot P et al 1993 Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol 330:15-31
19. Maisonpierre PC, Barrezueta NX, Yancopoulos GD 1993 Ehk-1 and Ehk-2: two novel members of the Eph receptor-like tyrosine kinase family with distinctive structures and neuronal expression. Oncogene 8:3277-3288
20. Mark MR, Scadden DT, Wang Z, Gu Q, Godowski PJ 1994 rse, a novel receptor-type tyrosine kinase with homology to Axl/Ufo, is expressed at high levels in the brain. J Biol Chem 269:10720-10728
21. Miyamoto M, Narumi S, Nagaoka A, Coyle JT 1989 Effects of continuous infusion of cholinergic drugs on memory impairment in rats with basal forebrain lesions. J Pharmacol Exp Ther 248:825-835
22. O'Bryan JP 1991 axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11:5016-5031
23. Olson L, Nordberg A, von Holst H et al 1992 Nerve growth factor affects 1 IC-nicotine binding, blood flow, EEG and verbal episodic memory in an Alzheimer patient. J Neural Transm Parkinson's Dis Dementia Sect 4:79-95
24. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW 1991 BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7:695-702
25. Raz V, Kelman Z, Avivi A, Neufeld G, Givol D, Yarden Y 1991 PCR-based identification of new receptors: molecular cloning of a receptor for fibroblast growth factors. Oncogene 6:753-760
26. Sajjadi FG, Pasquale EB 1993 Five novel avian Eph-related tyrosine kinases are differently expressed. Oncogene 8:1807-1813
27. Thoenen H, Bandtlow C, Heumann R 1987 The physiological function of nerve growth factor in the central nervous system: comparison with the periphery. Rev Physiol Biochem Pharmacol 109:145-178
28. Tilson HA, McLamb RL, Shaw S, Rogers BC, Pediaditakis P, Cook L 1988 Radialmaze deficits produced by colchicine administered into the area of the nucleus basalis are ameliorated by cholinergic agents. Brain Res 438:83-94
29. Voytko ML, Olton DS, Richardson RT, German LK, Tobin JR, Price DL 1994 Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 14:167-186
30. Will B, Hefti F 1985 Behavioral and neurochemical effects of chronic intraventricular injections of nerve growth factor in adult rats with fimbria lesions. Behav Brain Res 17:17-24
31. Yao DL, Liu X, Hudson LD, Webster HD 1995 Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encelphalomyelitis. Proc Natl Acad Sci USA 92:6190-6194
32. Zhou R, Copeland TD, Kromer LF, Schulz NT 1994 Isolation and characterization of Bsk, a growth factor receptor-like tyrosine kinase associated with the limbic system. J Neurosci Res 37:129-143